Increasing therapy‐related myeloid neoplasms in multiple myeloma

• DOI: 10.1111/eci.13050
• Publication Date: 2018-11-13T14:17:37Z
• Authors: Mariana Fernández...; Diego Salmerón; María Dolores Chi...; Tzu H. Chen‐Liang; Ana M. Hurtado; María D. García Malo; Francisco J. Ortuño; Vanessa Roldán; Vicente Vicente; Andrés Jerez; Felipe De Arriba
• Keywords: Myeloid leukaemia

Despite the longer survival achieved in multiple myeloma (MM) patients due to new therapy strategies, a concern is emerging regarding an increased risk of secondary primary malignancies (SPMs) and how characterize those at risk. We performed retrospective study covering 28-year follow-up period (1991-2018) tertiary single institution.Data 403 MM were recorded compared with epidemiologic register population area covered by our centre, calculating standardize incidence ratio (SIR) for different types SPMs diagnosed cohort. Fine Gray regression models used identify factors SPMs.Out patients, 23 (5.7%) developed SPMs: 13 therapy-related myeloid (TRM) (10 them (77%) myelodysplastic syndrome (MDS), 1 acute lymphoid leukaemia 9 solid neoplasms. In cohort, relative MDS was significantly higher than general population. Survival TRM poor median 4 months from diagnosis, most showed complex karyotype. Within subset, multivariable analysis that previously received prolonged treatment lenalidomide (>18 months).Though improvement outcome during last decades unprecedented achievement, it has been accompanied rise cytogenetic profile prognosis are need improved biologic therapeutic approach.